Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?-Reference-Cited by-同舟云学术

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

Published:2019-09-06 Issue:3 Volume:178 Page:597-605
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Steenbruggen T. G.,Bouwer N. I.,Smorenburg C. H.,Rier H. N.,Jager A.,Beelen K.,ten Tije A. J.,de Jong P. C.,Drooger J. C.,Holterhues C.,Kitzen J. J. E. M.,Levin M. -D.,Sonke G. S.

Funder

Stichting A Sister's Hope

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05427-1.pdf

Reference35 articles.

1. Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol Off J Eur Soc Med Oncol 29:1634–1657. https://doi.org/10.1093/annonc/mdy192

2. Sundquist M, Brudin L, Tejler G (2017) Improved survival in metastatic breast cancer 1985-2016. Breast 31:46–50. https://doi.org/10.1016/j.breast.2016.10.005

3. Weide R, Feiten S, Friesenhahn V et al (2014) Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus 3:535. https://doi.org/10.1186/2193-1801-3-535

4. Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98. https://doi.org/10.1200/JCO.2008.19.9844

5. Mendes D, Alves C, Afonso N et al (2015) The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer—a systematic review. Breast Cancer Res 17:140. https://doi.org/10.1186/s13058-015-0648-2

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial;Clinical Breast Cancer;2024-07

2. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer;Breast Cancer Research;2023-10-04

3. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression;Scientific Reports;2023-05-31

4. Oligometastatic breast cancer to parotid gland with complete response;Breast Disease;2023-03-08

5. Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution;Breast Cancer Research and Treatment;2023-02-15